Navigation Links
Pivotal Trial Data Demonstrate NeuroPace RNS(R) System Reduced Seizures in People With Epilepsy
Date:12/7/2009

rienced a mean percentage reduction of 29 percent in their disabling seizures compared to 14 percent reduction for those in the sham stimulation group. In the long term, open label period of the trial, at least 12 weeks of data were available for 171 study participants; 47 percent of these subjects experienced a 50 percent or greater reduction in their seizure frequency based on their most recent 12 weeks of data, as compared to their baseline.

The trial also demonstrated a serious adverse event rate less than comparative surgical procedures. There were no serious unanticipated device related adverse events reported in the trial. There was no difference between the treatment and sham stimulation groups when comparing the rate of adverse events, including depression, memory impairment and anxiety.

To download a copy of the press kit and images of the RNS System, please visit: http://bit.ly/RNSSystem

About the RNS System

The RNS System is designed with novel technology to detect abnormal electrical activity in the brain and then deliver small amounts of electrical stimulation to suppress the abnormal activity before any seizure symptoms occur. This type of treatment is called responsive stimulation and differs from deep brain stimulation, which delivers stimulation continuously or on a pre-set schedule. With the RNS System, physicians have the ability to non-invasively program the detection and stimulation parameters of an implanted RNS Neurostimulator specifically for individual patients.

About the RNS System Pivotal Clinical Trial

Trial Patient Population

The RNS System Pivotal Clinical Investigation is a randomized, double-blind, sham stimulation controlled investigation that included 191 people implanted with the RNS System across 31 sites. All subjects in the study were required to be 18 or older and have partia
'/>"/>

SOURCE NeuroPace, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
2. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
3. Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study
4. Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
5. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
6. Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
7. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
8. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
9. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
10. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
11. Pivotal Data Show Bronchial Thermoplasty Can Improve Quality of Life and Reduce Asthma Attacks and Emergency Room Visits for Adults with Severe Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
(Date:7/30/2015)... July 30, 2015 /PRNewswire/ - Anything Technologies Media, Inc. ... Frontier Indoor Garden Solutions (FIGS), www.frontiergarden.com ... and the Project Manager for a My Compassion ... American Group located in Alaska.  The project will ... its finance Teaming Partners. The first phase of ...
(Date:7/30/2015)... 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... webcast at 5:00 p.m. Eastern Time (2:00 p.m. Pacific ... quarter 2015 financial results and provide a corporate update. ... Global Select Market closes that day. The ... domestic callers and 914.495.8552 for international callers. Please specify ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... Health Care Conference. Piper Jaffray Health Care Conference ... 2:00 p.m. ET A ... at http://www.avanir.com . About Avanir Pharmaceuticals, ...
... 2011  Cara Therapeutics, Inc. today announced the initiation ... an oral formulation of its peptide-based, kappa opioid ... trial is expected to enroll up to 60 ... evaluate the pharmacokinetic, pharmacodynamic and safety profile of ...
Cached Medicine Technology:Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist 2
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on ... OncLive’s editorial and marketing groups will help spread the news about the center’s ...
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading ... of Inclusive™ magazine, its multimedia publication focused on implant dentistry, is now available ... issue, Volume 6, Issue 2, as well as past issues of the dental ...
(Date:7/30/2015)... FL (PRWEB) , ... July 30, 2015 , ... On ... than $2 billion in taxpayer money to fund the state’s large prison system, which ... country with the highest rates of incarceration. In light of President Obama’s recent reduction ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
Breaking Medicine News(10 mins):Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... In its efforts to promote Kerala as an ideal destination for ... in the US, Britain, Dubai, Muscat, Kuwait, Sri Lanka and the ... it has to be systematic and we have asked the CII ... the policy and when we announce it shortly we would become ...
... outbreak in the Sydney CBD is linked to the Royal ... suspect//. However, they could not confirm the link. ... bacteria belonging to the Legionella family, Legionella pneumophilia, have been ... in the Circular Quay area on New Year's Eve. ...
... University and pediatric specialists at Baylor College of Medicine have ... as passkeys that allows drugs to enter cancer cells. ... of the journal Organic and Biomolecular Chemistry. ,All ... Cell walls, or membranes, form a protective cocoon around the ...
... Hopkins Researchers have shown that a drug commonly used ... engineered mice with Marfan syndrome and also prevents muscle ... ,The results are reported online this week at Nature ... Harry "Hal" Dietz, M.D., discovered that treating Marfan mice ...
... took more control over choosing their breast cancer surgeon were ... surgeons and at a hospital affiliated with an accredited cancer ... or their health plan, according to a study led by ... ,The study looked at 1,844 women recently diagnosed with ...
... to have a beneficial effect on the health of men. Some ... the following // ,Vegetables like tomatoes, carrot, garlic and whole ... like oysters, shrimps and deep sea fish has the similar effect ... and nutrients and also help in secretion of gastric acid. The ...
Cached Medicine News:Health News:Buckyballs Used as 'Passkey' into Cancer Cells 2Health News:Common BP Drug Treats Muscular Dystrophy 2Health News:Common BP Drug Treats Muscular Dystrophy 3Health News:Are Women Seeing the Most Experienced Breast Cancer Surgeons? 2
Reptilase-Time from Bothrops atrox...
Pefakit PiCT UFH Controls...
Pefakit PiCT LMWH Calibrators...
APTT (Ellagic Acid) - 10 ml...
Medicine Products: